ACTRN12606000386538
Completed
Phase 2
A Pilot Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Out-Patient Based Vinorelbine, Gemcitabine and Pegfilgrastim or Pegfilgrastim, Gemcitabine, Ifosfamide and Vinorelbine Salvage Therapies in the Treatment of Relapsed/Refractory CD20+ Non-Hodgkin Lymphomas to Improve the Outcome of Quality of Life and to Minimise Inpatient Stay.
Associate Professor Andrew Spencer0 sites12 target enrollmentSeptember 4, 2006
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Relapsed and refractory CD20+ lymphoma
- Sponsor
- Associate Professor Andrew Spencer
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Relapsed or primary refractory CD20\+ NHL, ECOG 0 – 2, Written informed consent.
Exclusion Criteria
- •Intention to proceed with any form of transplant therapy following fewer than 2 cycles of protocol salvage therapy, Bilirubin \> 50µmol/litre unless secondary to lymphoma, Creatinine \> 2 x upper limit of normal unless secondary to lymphoma, Absolute neutrophil count \<0\.5 x 109/litre and / or platelets \< 50 x 109/litre unless secondary to lymphoma, Relapse within 6 months of a prior transplant procedure (autologous or allogeneic), Known sensitivity to E coli derived preparations.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical Study to evaluate the Efficacy and Safety of Lactobacillus Probiotic Suppositories on Vaginal Health and pH.CTRI/2022/01/039560Vedic Lifesciences Pvt Ltd69
Completed
Not Applicable
The Pilot Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid TumorsNeoplasmsKCT0002997Samsung Medical Center25
Not yet recruiting
Not Applicable
A Pilot study to Evaluate the Efficacy and Safety of Autologous Adipose tissue-derived Stromal Vascular Fraction(SVF) treatment for the Patients with articular cartilage injury of the kneeKCT0005566Samsung Medical Center3
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.EUCTR2007-004337-41-FRGENFIT30
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind, parallel group, placebo-controlled and randomized study.patients presenting with impaired glucose tolerance and abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10036481Term: Pre-diabetesMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2009-011003-23-FRGENFIT40